| Project/Area Number |
09670239
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Experimental pathology
|
|---|
| Research Institution | Tokai University |
|---|
Principal Investigator |
KIJIMA Hiroshi Tokai University School of Medicine Assistant Professor, 医学部, 講師 (90204859)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMAZAKI Hitoshi Tokai University School of Medicine Assistant Professor, 医学部, 講師 (20191273)
NAKAMURA Masato Tokai University School of Medicine Assistant Professor, 医学部, 講師 (00164335)
|
|---|
| Project Period (FY) |
1997 – 1998
|
| Project Status |
Completed (Fiscal Year 1998)
|
| Budget Amount *help |
¥3,200,000 (Direct Cost: ¥3,200,000)
Fiscal Year 1998: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 1997: ¥2,100,000 (Direct Cost: ¥2,100,000)
|
|---|
| Keywords | ribozyme / RNA enzyme / gene modulation / pancreatic cancer / ras oncogene / mice model |
|---|
| Research Abstract |
Pancreatic cancer is one on lethal human cancers, and development of its new therapeutic strategy is eagerly required today. Point mutation in the K-ras gene is observed at a high incidence in human pancreatic carcinomas. These alterations can be used as potential targets for specific ribozyme-mediated reversal of the malignant phenotype. We have demonstrated the efficacy of a hammerhead ribozyme directed against codon 12 of the activated K-ras gene in a Capan-1 human pancreatic carcinoma cell line. To develop this strategy into a therapeutic application, we designed a recombinant adenovirus encoding a gene cassette for the anti-K-ras ribozyme. By using this recombinant adenovirus in a mice model system, it was possible to accomplish efficient reversion of the malignant phenotype in human pancreatic tumors with K- ras gene mutation. The high efficiency adenoviral-mediated delivery of anti-oncogene ribozyme could emerge as a significant gene therapy strategy against human malignancies.
|
